Synthesis, α-Glucosidase, α-Amylase, and Aldol Reductase Inhibitory Activity with Molecular Docking Study of Novel Imidazo[1,2-a]pyridine Derivatives

ArticleAçık Erişim

Özet

Inhibition ofaldose reductase (AR), α-glycosidase (α-GLY), and α-amylase (α-AMY) are some of the essential targets in diabetes mellitus (DM). Here, a series of imidazo[1,2-a]pyridine-based 1,3,4-thiadiazole derivatives (8a-k) were successfully synthesized and characterized using 1H NMR, 13C NMR, and HRMS spectroscopic techniques. The inhibition effects of the synthesized derivatives against AR, α-GLY, and α-AMY were evaluated using both in vitro and in silico methods. In vitro studies revealed that the derivatives (8a-k) showed significant inhibition activity. The results showed that the novel derivatives (8a-k) demonstrated potential inhibitory activity, with KI values covering the following ranges: 23.47 ± 2.40 to 139.60 ± 13.33 nM for AR and 6.09 ± 0.37 to 119.80 ± 12.31 μM for α-GLY, with IC50 values 81.14 to 153.51 μM for α-AMY. Furthermore, many of these compounds exhibited high inhibition activity, while some of them showed higher potency than the reference compounds. Molecular docking of the target compounds was carried out in the active sites of AR (PDB ID: 4JIR) and α-GLY (PDB ID: 5NN8). © 2024 The Authors. Published by American Chemical Society.

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/11267Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.1021/acsomega.4c05619Yayıncı resmi DOI adresi
Tam Kayıt
AlanDeğerDil
dc.contributor.authorKaya, Betül
dc.contributor.authorAcar Çevik, Ulviye
dc.contributor.authorÇiftçi, Bilge
dc.contributor.authorDuran, Hatice Esra
dc.contributor.authorTürkeş, Cüneyt
dc.contributor.authorIşık, Mesut
dc.contributor.authorBostancı, Hayrani Eren
dc.contributor.authorKaplancıklı, Zafer Asım
dc.contributor.authorBeydemir, Şükrü
dc.date.accessioned2026-10-18T20:26:20.338163620Z
dc.date.available2026-10-18T20:26:20.338163620Z
dc.date.issued2024
dc.description.abstractInhibition ofaldose reductase (AR), α-glycosidase (α-GLY), and α-amylase (α-AMY) are some of the essential targets in diabetes mellitus (DM). Here, a series of imidazo[1,2-a]pyridine-based 1,3,4-thiadiazole derivatives (8a-k) were successfully synthesized and characterized using 1H NMR, 13C NMR, and HRMS spectroscopic techniques. The inhibition effects of the synthesized derivatives against AR, α-GLY, and α-AMY were evaluated using both in vitro and in silico methods. In vitro studies revealed that the derivatives (8a-k) showed significant inhibition activity. The results showed that the novel derivatives (8a-k) demonstrated potential inhibitory activity, with KI values covering the following ranges: 23.47 ± 2.40 to 139.60 ± 13.33 nM for AR and 6.09 ± 0.37 to 119.80 ± 12.31 μM for α-GLY, with IC50 values 81.14 to 153.51 μM for α-AMY. Furthermore, many of these compounds exhibited high inhibition activity, while some of them showed higher potency than the reference compounds. Molecular docking of the target compounds was carried out in the active sites of AR (PDB ID: 4JIR) and α-GLY (PDB ID: 5NN8). © 2024 The Authors. Published by American Chemical Society.
dc.description.sponsorshipThe authors present their thanks to Anadolu University for NMR spectra.
dc.identifier.doi10.1021/acsomega.4c05619
dc.identifier.endpage42914
dc.identifier.issn2470-1343
dc.identifier.issue42
dc.identifier.pmcidPMC11500159
dc.identifier.pmid39464438
dc.identifier.scopus2-s2.0-85206802391
dc.identifier.startpage42905
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/11267
dc.identifier.volume9
dc.language.isoen
dc.publisherAmerican Chemical Society
dc.relation.ispartofACS Omega
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titleSynthesis, α-Glucosidase, α-Amylase, and Aldol Reductase Inhibitory Activity with Molecular Docking Study of Novel Imidazo[1,2-a]pyridine Derivatives
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus27
rdl.departmentDepartment of Biochemistry, Faculty of Pharmacy, Erzincan Binali Yıldırım University, 24002 Erzincan, Turkey.
rdl.oa.statusgold
rdl.source.indexSCOPUS
rdl.source.indexPUBMED